CASIF — CASI Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.06m
- $38.79m
- $20.71m
Brief: Casi Pharmaceuticals Statement On Status Under Holding Foreign Companies Accountable Act
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Casi Pharmaceuticals Inc Says As Of Dec. 31, 2021, It Had Cash And Cash Equivalents Of $38.7 Mln
Casi Pharmaceuticals Inc Expected To Post A Loss Of 6 Cents A Share: Earnings Preview
Brief: Casi Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In China
Brief: Casi Pharmaceuticals Sees Q4 Revenue About $9.12 Mln
CASI Pharmaceuticals jumps as partner BioInvent's lymphoma treatment gets orphan drug tag
Brief: CASI Pharmaceuticals Partner, Bioinvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA
Brief: CASI Pharmaceuticals Announces CNCT19 (CD19 Car-T) Granted Orphan Drug Designation By The U.S. FDA
U.S. STOCKS ON THE MOVE-Tesla, Container Store, Apple
U.S. STOCKS ON THE MOVE-Tesla, Armstrong Flooring, Immix Biopharma, BlueCity
U.S. STOCKS ON THE MOVE-Tesla, Armstrong Flooring, Carnival Corp, BlueCity
CASI Pharmaceuticals drops after Nasdaq serves deficiency notice
Brief: CASI Pharmaceuticals, Receives Nasdaq Deficiency Notice
Brief: Casi Pharmaceuticals Announces Stock Repurchase Program
Brief: Bioinvent And CASI Pharmaceuticals CTA Approval For Clinical Studies In China
Brief: CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In China
CASI Pharma rises on strong cancer drug sales
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended In September: Earnings Summary